CN101347508B - 防己有效组分及其制备方法 - Google Patents
防己有效组分及其制备方法 Download PDFInfo
- Publication number
- CN101347508B CN101347508B CN2007101232792A CN200710123279A CN101347508B CN 101347508 B CN101347508 B CN 101347508B CN 2007101232792 A CN2007101232792 A CN 2007101232792A CN 200710123279 A CN200710123279 A CN 200710123279A CN 101347508 B CN101347508 B CN 101347508B
- Authority
- CN
- China
- Prior art keywords
- minute
- radix stephaniae
- stephaniae tetrandrae
- ethanol
- mobile phase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 26
- 241001643409 Sinomenium acutum Species 0.000 title claims description 26
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 121
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims abstract description 63
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims abstract description 39
- 239000000203 mixture Substances 0.000 claims abstract description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 13
- 238000010828 elution Methods 0.000 claims abstract description 9
- 238000004440 column chromatography Methods 0.000 claims abstract description 6
- 239000002904 solvent Substances 0.000 claims abstract description 5
- 235000019441 ethanol Nutrition 0.000 claims description 40
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 39
- 239000003480 eluent Substances 0.000 claims description 23
- 238000004262 preparative liquid chromatography Methods 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 9
- 238000010992 reflux Methods 0.000 claims description 9
- 238000001035 drying Methods 0.000 claims description 8
- 230000008859 change Effects 0.000 claims description 7
- 239000012141 concentrate Substances 0.000 claims description 7
- 238000000926 separation method Methods 0.000 claims description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 6
- 238000002481 ethanol extraction Methods 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 5
- 230000001476 alcoholic effect Effects 0.000 claims description 5
- 230000000259 anti-tumor effect Effects 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 239000000706 filtrate Substances 0.000 claims description 2
- 239000000284 extract Substances 0.000 abstract description 9
- 239000007791 liquid phase Substances 0.000 abstract 1
- 239000012071 phase Substances 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 75
- 230000001629 suppression Effects 0.000 description 35
- 239000000243 solution Substances 0.000 description 33
- 239000003814 drug Substances 0.000 description 32
- 230000004083 survival effect Effects 0.000 description 32
- 239000012531 culture fluid Substances 0.000 description 30
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 29
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 21
- 239000007788 liquid Substances 0.000 description 20
- 238000002156 mixing Methods 0.000 description 18
- 229960000583 acetic acid Drugs 0.000 description 13
- 238000010790 dilution Methods 0.000 description 12
- 239000012895 dilution Substances 0.000 description 12
- 239000012362 glacial acetic acid Substances 0.000 description 10
- 238000004113 cell culture Methods 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 210000004881 tumor cell Anatomy 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
- 239000012490 blank solution Substances 0.000 description 8
- 238000004128 high performance liquid chromatography Methods 0.000 description 8
- -1 dimethyl tetrandrine Chemical compound 0.000 description 7
- 239000002552 dosage form Substances 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 239000013543 active substance Substances 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 230000000144 pharmacologic effect Effects 0.000 description 6
- WVTKBKWTSCPRNU-KYJUHHDHSA-N (+)-Tetrandrine Chemical compound C([C@H]1C=2C=C(C(=CC=2CCN1C)OC)O1)C(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2C[C@@H]2N(C)CCC3=CC(OC)=C(OC)C1=C23 WVTKBKWTSCPRNU-KYJUHHDHSA-N 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 238000005303 weighing Methods 0.000 description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- 229930195725 Mannitol Natural products 0.000 description 4
- 235000008504 concentrate Nutrition 0.000 description 4
- 230000009514 concussion Effects 0.000 description 4
- 230000000857 drug effect Effects 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 230000008020 evaporation Effects 0.000 description 4
- 239000003292 glue Substances 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000594 mannitol Substances 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 239000002547 new drug Substances 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 210000002826 placenta Anatomy 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- NWXMGUDVXFXRIG-WESIUVDSSA-N (4s,4as,5as,6s,12ar)-4-(dimethylamino)-1,6,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O NWXMGUDVXFXRIG-WESIUVDSSA-N 0.000 description 3
- 229930195573 Amycin Natural products 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 235000011054 acetic acid Nutrition 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 238000004737 colorimetric analysis Methods 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003797 essential amino acid Substances 0.000 description 3
- 235000020776 essential amino acid Nutrition 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 239000012737 fresh medium Substances 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 238000012856 packing Methods 0.000 description 3
- WVTKBKWTSCPRNU-UHFFFAOYSA-N rac-Tetrandrin Natural products O1C(C(=CC=2CCN3C)OC)=CC=2C3CC(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2CC2N(C)CCC3=CC(OC)=C(OC)C1=C23 WVTKBKWTSCPRNU-UHFFFAOYSA-N 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- DFOCUWZXJBAUSQ-UHFFFAOYSA-N Berbamine Natural products O1C(C(=CC=2)O)=CC=2CC(C=23)N(C)CCC3=CC(OC)=C(OC)C=2OC(=CC=23)C(OC)=CC=2CCN(C)C3CC2=CC=C1C=C2 DFOCUWZXJBAUSQ-UHFFFAOYSA-N 0.000 description 2
- DFOCUWZXJBAUSQ-URLMMPGGSA-N Berbamine Chemical compound C([C@@H]1N(C)CCC=2C=C(C(OC=3C(OC)=C(OC)C=C4CCN(C)[C@@H](C=34)CC=3C=C(C(=CC=3)O)O3)=CC=21)OC)C1=CC=C3C=C1 DFOCUWZXJBAUSQ-URLMMPGGSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241001299553 Ilex chinensis Species 0.000 description 2
- 241001100935 Ilex purpurea Species 0.000 description 2
- 235000003366 Ilex purpurea Nutrition 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 238000007605 air drying Methods 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- SHWNNYZBHZIQQV-UHFFFAOYSA-L calcium;disodium;2-[2-[bis(carboxylatomethyl)azaniumyl]ethyl-(carboxylatomethyl)azaniumyl]acetate Chemical compound [Na+].[Na+].[Ca+2].[O-]C(=O)C[NH+](CC([O-])=O)CC[NH+](CC([O-])=O)CC([O-])=O SHWNNYZBHZIQQV-UHFFFAOYSA-L 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- LKLWVKCEYSPQHL-KKSFZXQISA-O cyclanoline Chemical compound C12=CC(O)=C(OC)C=C2CC[N@+]2(C)[C@H]1CC1=CC=C(OC)C(O)=C1C2 LKLWVKCEYSPQHL-KKSFZXQISA-O 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000000105 evaporative light scattering detection Methods 0.000 description 2
- IIQSJHUEZBTSAT-VMPREFPWSA-N fangchinoline Chemical compound C([C@H]1C=2C=C(C(=CC=2CCN1C)OC)O1)C(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2C[C@@H]2N(C)CCC3=CC(OC)=C(O)C1=C23 IIQSJHUEZBTSAT-VMPREFPWSA-N 0.000 description 2
- IIQSJHUEZBTSAT-UHFFFAOYSA-N fangchinoline Natural products O1C(C(=CC=2CCN3C)OC)=CC=2C3CC(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2CC2N(C)CCC3=CC(OC)=C(O)C1=C23 IIQSJHUEZBTSAT-UHFFFAOYSA-N 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012567 medical material Substances 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 238000010298 pulverizing process Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 2
- 235000019345 sodium thiosulphate Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 229940032147 starch Drugs 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- LXAHHHIGZXPRKQ-UHFFFAOYSA-N 5-fluoro-2-methylpyridine Chemical compound CC1=CC=C(F)C=N1 LXAHHHIGZXPRKQ-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Natural products OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 206010047601 Vitamin B1 deficiency Diseases 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003005 anticarcinogenic agent Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 208000002894 beriberi Diseases 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- NKWPZUCBCARRDP-UHFFFAOYSA-L calcium bicarbonate Chemical compound [Ca+2].OC([O-])=O.OC([O-])=O NKWPZUCBCARRDP-UHFFFAOYSA-L 0.000 description 1
- 229910000020 calcium bicarbonate Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 201000005619 esophageal carcinoma Diseases 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 229930013397 isoquinoline alkaloid Natural products 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 150000003376 silicon Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 229940080313 sodium starch Drugs 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- JFJZZMVDLULRGK-URLMMPGGSA-O tubocurarine Chemical compound C([C@H]1[N+](C)(C)CCC=2C=C(C(=C(OC3=CC=C(C=C3)C[C@H]3C=4C=C(C(=CC=4CCN3C)OC)O3)C=21)O)OC)C1=CC=C(O)C3=C1 JFJZZMVDLULRGK-URLMMPGGSA-O 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
防己B03组分 | 阴性 | 空白 | 阳性 | |
平均细胞存活数 | 0.084 | 0.79 | 0.07 | 0.11 |
抑制率(%) | 98.06 | 0.00 | 100.0 | 94.79 |
RSD(%) | 4.86 | 1.75 | 6.712 | 2.892 |
防己B04组分 | 阴性 | 空白 | 阳性 | |
平均细胞存活数 | 0.089 | 0.79 | 0.07 | 0.11 |
抑制率(%) | 97.36 | 0.00 | 100.0 | 94.79 |
RSD(%) | 3.31 | 1.75 | 6.712 | 2.892 |
防己B05组分 | 阴性 | 空白 | 阳性 | |
平均细胞存活数 | 0.080 | 0.79 | 0.07 | 0.11 |
抑制率(%) | 98.65 | 0.00 | 100.0 | 94.79 |
RSD(%) | 6.42 | 1.75 | 6.712 | 2.892 |
防己B06组分 | 阴性 | 空白 | 阳性 | |
平均细胞存活数 | 0.078 | 0.79 | 0.07 | 0.11 |
抑制率(%) | 98.85 | 0.00 | 100.0 | 94.79 |
RSD(%) | 5.84 | 1.75 | 6.712 | 2.892 |
防己B07组分 | 阴性 | 空白 | 阳性 | |
平均细胞存活数 | 0.087 | 0.79 | 0.07 | 0.11 |
抑制率(%) | 97.71 | 0.00 | 100.0 | 94.79 |
RSD(%) | 3.59 | 1.75 | 6.712 | 2.892 |
防己B08组分 | 阴性 | 空白 | 阳性 | |
平均细胞存活数 | 0.086 | 0.79 | 0.07 | 0.11 |
抑制率(%) | 97.85 | 0.00 | 100.0 | 94.79 |
RSD(%) | 5.53 | 1.75 | 6.712 | 2.892 |
防己B09组分 | 阴性 | 空白 | 阳性 | |
平均细胞存活数 | 0.09 | 0.79 | 0.07 | 0.11 |
抑制率(%) | 96.98 | 0.00 | 100.0 | 94.79 |
RSD(%) | 6.440 | 1.75 | 6.712 | 2.892 |
防己B10组分 | 阴性 | 空白 | 阳性 | |
平均细胞存活数 | 0.11 | 0.79 | 0.07 | 0.11 |
抑制率(%) | 94.58 | 0.00 | 100.0 | 94.79 |
RSD(%) | 0.917 | 1.75 | 6.712 | 2.892 |
防己B03组分 | 阴性 | 空白 | 阳性 | |
平均细胞存活数 | 0.075 | 0.493 | 0.069 | 0.086 |
抑制率(%) | 98.644 | 0.000 | 100.000 | 96.050 |
防己B04组分 | 阴性 | 空白 | 阳性 | |
平均细胞存活数 | 0.072 | 0.493 | 0.069 | 0.086 |
抑制率(%) | 99.351 | 0.000 | 100.000 | 96.050 |
RSD(%) | 4.605 | 4.450 | 6.498 | 3.067 |
防己B05组分 | 阴性 | 空白 | 阳性 | |
平均细胞存活数 | 0.068 | 0.493 | 0.069 | 0.086 |
抑制率(%) | 100.177 | 0.000 | 100.000 | 96.050 |
RSD(%) | 2.502 | 4.450 | 6.498 | 3.067 |
防己B06组分 | 阴性 | 空白 | 阳性 | |
平均细胞存活数 | 0.069 | 0.493 | 0.069 | 0.086 |
抑制率(%) | 100.000 | 0.000 | 100.000 | 96.050 |
RSD(%) | 1.183 | 4.450 | 6.498 | 3.067 |
防己B07组分 | 阴性 | 空白 | 阳性 | |
平均细胞存活数 | 0.073 | 0.499 | 0.072 | 0.093 |
抑制率(%) | 99.766 | 0.000 | 100.000 | 95.199 |
RSD(%) | 5.126 | 5.499 | 4.003 | 5.477 |
防己B08组分 | 阴性 | 空白 | 阳性 | |
平均细胞存活数 | 0.079 | 0.499 | 0.072 | 0.093 |
抑制率(%) | 98.478 | 0.000 | 100.000 | 95.199 |
RSD(%) | 5.553 | 5.499 | 4.003 | 5.477 |
防己B09组分 | 阴性 | 空白 | 阳性 | |
平均细胞存活数 | 0.067 | 0.499 | 0.072 | 0.093 |
抑制率(%) | 101.112 | 0.000 | 100.000 | 95.199 |
RSD(%) | 2.540 | 5.499 | 4.003 | 5.477 |
防己B10组分 | 阴性 | 空白 | 阳性 | |
平均细胞存活数 | 0.083 | 0.499 | 0.072 | 0.093 |
抑制率(%) | 97.541 | 0.000 | 100.000 | 95.199 |
RSD(%) | 8.310 | 5.499 | 4.003 | 5.477 |
防己B03组分 | 阴性 | 空白 | 阳性 | |
平均细胞存活数 | 0.338 | 1.995 | 0.072 | 0.095 |
抑制率(%) | 86.150 | 0.000 | 100.000 | 98.817 |
RSD(%) | 7.855 | 1.917 | 4.167 | 2.340 |
防己B04组分 | 阴性 | 空白 | 阳性 | |
平均细胞存活数 | 0.298 | 1.995 | 0.072 | 0.095 |
抑制率(%) | 88.235 | 0.000 | 100.000 | 98.817 |
RSD(%) | 9.477 | 1.917 | 4.167 | 2.340 |
防己B05组分 | 阴性 | 空白 | 阳性 | |
平均细胞存活数 | 0.072 | 1.995 | 0.072 | 0.095 |
抑制率(%) | 100.000 | 0.000 | 100.000 | 98.817 |
RSD(%) | 4.676 | 1.917 | 4.167 | 2.340 |
防己B06组分 | 阴性 | 空白 | 阳性 | |
平均细胞存活数 | 0.075 | 1.995 | 0.072 | 0.095 |
防己B07组分 | 阴性 | 空白 | 阳性 | |
平均细胞存活数 | 0.076 | 1.768 | 0.075 | 0.097 |
抑制率(%) | 99.941 | 0.000 | 100.000 | 98.715 |
RSD(%) | 1.861 | 1.882 | 2.285 | 4.416 |
防己B08组分 | 阴性 | 空白 | 阳性 | |
平均细胞存活数 | 0.084 | 1.768 | 0.075 | 0.097 |
抑制率(%) | 99.498 | 0.000 | 100.000 | 98.715 |
RSD(%) | 5.311 | 1.882 | 2.285 | 4.416 |
防己B09组分 | 阴性 | 空白 | 阳性 | |
平均细胞存活数 | 0.090 | 1.768 | 0.075 | 0.097 |
抑制率(%) | 99.099 | 0.000 | 100.000 | 98.715 |
RSD(%) | 7.643 | 1.882 | 2.285 | 4.416 |
防己B10组分 | 阴性 | 空白 | 阳性 | |
平均细胞存活数 | 0.121 | 1.768 | 0.075 | 0.097 |
抑制率(%) | 97.263 | 0.000 | 100.000 | 98.715 |
RSD(%) | 7.790 | 1.882 | 2.285 | 4.416 |
防己B03组分 | 阴性 | 空白 | 阳性 | |
平均细胞存活数 | 0.515 | 1.774 | 0.075 | 0.469 |
抑制率(%) | 74.088 | 0.000 | 100.000 | 76.795 |
RSD(%) | 1.531 | 1.880 | 5.657 | 4.049 |
防己B04组分 | 阴性 | 空白 | 阳性 | |
平均细胞存活数 | 0.354 | 1.774 | 0.075 | 0.469 |
抑制率(%) | 83.593 | 0.000 | 100.000 | 76.795 |
RSD(%) | 6.550 | 1.880 | 5.657 | 4.049 |
防己B05组分 | 阴性 | 空白 | 阳性 | |
平均细胞存活数 | 0.066 | 1.774 | 0.075 | 0.469 |
抑制率(%) | 100.530 | 0.000 | 100.000 | 76.795 |
RSD(%) | 4.545 | 1.880 | 5.657 | 4.049 |
防己B06组分 | 阴性 | 空白 | 阳性 | |
平均细胞存活数 | 0.071 | 1.391 | 0.070 | 0.362 |
抑制率(%) | 99.943 | 0.000 | 100.000 | 77.877 |
RSD(%) | 3.892 | 2.739 | 2.935 | 5.792 |
防己B07组分 | 阴性 | 空白 | 阳性 | |
平均细胞存活数 | 0.232 | 1.391 | 0.070 | 0.362 |
抑制率(%) | 87.762 | 0.000 | 100.000 | 77.877 |
RSD(%) | 9.500 | 2.739 | 2.935 | 5.792 |
防己B08组分 | 阴性 | 空白 | 阳性 | |
平均细胞存活数 | 0.250 | 1.391 | 0.070 | 0.362 |
抑制率(%) | 86.349 | 0.000 | 100.000 | 77.877 |
RSD(%) | 3.326 | 2.739 | 2.935 | 5.792 |
防己B09组分 | 阴性 | 空白 | 阳性 | |
平均细胞存活数 | 0.130 | 0.214 | 0.099 | 0.138 |
抑制率(%) | 73.043 | 0.000 | 100.000 | 66.522 |
RSD(%) | 4.283 | 2.643 | 5.345 | 3.279 |
防己B10组分 | 阴性 | 空白 | 阳性 | |
平均细胞存活数 | 0.126 | 0.179 | 0.090 | 0.100 |
抑制率(%) | 59.831 | 0.000 | 100.000 | 88.483 |
RSD(%) | 2.627 | 3.251 | 5.092 | 4.103 |
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2007101232792A CN101347508B (zh) | 2007-07-20 | 2007-07-20 | 防己有效组分及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2007101232792A CN101347508B (zh) | 2007-07-20 | 2007-07-20 | 防己有效组分及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101347508A CN101347508A (zh) | 2009-01-21 |
CN101347508B true CN101347508B (zh) | 2012-02-15 |
Family
ID=40266589
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2007101232792A Expired - Fee Related CN101347508B (zh) | 2007-07-20 | 2007-07-20 | 防己有效组分及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101347508B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111153909B (zh) * | 2020-01-17 | 2022-05-17 | 石药集团江西金芙蓉药业股份有限公司 | 一种粉防己中甲、乙素双模板分子印迹提纯方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1903250A (zh) * | 2005-07-29 | 2007-01-31 | 天津天士力现代中药研究开发有限公司 | 一种丹参药材的提取分离方法 |
-
2007
- 2007-07-20 CN CN2007101232792A patent/CN101347508B/zh not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1903250A (zh) * | 2005-07-29 | 2007-01-31 | 天津天士力现代中药研究开发有限公司 | 一种丹参药材的提取分离方法 |
Non-Patent Citations (2)
Title |
---|
甄攀.粉防己和木防己多糖的含量测定.《张家口医学院学报》.2003,第20卷(第2期),11-13. * |
胡延默等.粉防己化学成分氧化防己碱和防己菲碱的化学结构.《药学学报》.1986,第21卷(第1期),29-34. * |
Also Published As
Publication number | Publication date |
---|---|
CN101347508A (zh) | 2009-01-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101433563B (zh) | 诃子有效组分及其制备方法与用途 | |
CN101347518B (zh) | 一种赤芍的有效组分及其制备方法与用途 | |
CN101347497B (zh) | 一种山豆根的有效组分及其制备方法与用途 | |
CN101428083B (zh) | 白鲜皮有效组分及其制备方法与用途 | |
CN101347521B (zh) | 一种威灵仙的有效组分及其制备方法与用途 | |
CN101347509B (zh) | 一种防己的有效组分及其制备方法 | |
CN101549000B (zh) | 白薇有效组分及其制备方法 | |
CN101433612B (zh) | 一种白鲜皮的有效组分及其制备方法与用途 | |
CN101347534B (zh) | 茜草有效组分及其制备方法 | |
CN101347508B (zh) | 防己有效组分及其制备方法 | |
CN101549048B (zh) | 一种马鞭草的有效组分及其制备方法 | |
CN101347467B (zh) | 一种喜树果的有效组分及其制备方法与用途 | |
CN101428071B (zh) | 一种白头翁的有效组分及其制备方法与用途 | |
CN101433571B (zh) | 王不留行有效组分及其制备方法与用途 | |
CN101433614B (zh) | 一种白鲜皮的有效组分及其制备方法与用途 | |
CN101347565B (zh) | 一种穿山龙的有效组分及其制备方法与用途 | |
CN101347502B (zh) | 一种夏枯草的有效组分及其制备方法与用途 | |
CN101428053B (zh) | 王不留行有效组分及其制备方法与用途 | |
CN101433693B (zh) | 一种姜黄的有效组分及其制备方法 | |
CN101433692B (zh) | 一种姜黄的有效组分及其制备方法与用途 | |
CN101507769B (zh) | 一种白鲜皮的有效组分及其制备方法与用途 | |
CN101549004B (zh) | 一种王不留行的有效组分及其制备方法 | |
CN101347468B (zh) | 喜树果有效组分及其制备方法与用途 | |
CN101433613B (zh) | 一种白鲜皮的有效组分及其制备方法与用途 | |
CN101433570B (zh) | 王不留行有效组分及其制备方法与用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: TASLY PHARMACEUTICAL GROUP CO., LTD. Free format text: FORMER NAME: TIANJIN TIANSHILI PHARMACEUTICAL CO., LTD. |
|
CP01 | Change in the name or title of a patent holder |
Address after: 300402 Tianjin Beichen Xinyi white road Liaohe Road No. 1 Patentee after: Tasly Pharmaceutical Group Co., Ltd. Address before: 300402 Tianjin Beichen Xinyi white road Liaohe Road No. 1 Patentee before: Tianjin Tianshili Pharmaceutical Co., Ltd. |
|
CP02 | Change in the address of a patent holder | ||
CP02 | Change in the address of a patent holder |
Address after: 300410 Tianjin city Beichen District Huaihe road and road intersection Dingjiang tianzhijiao Park forensic Center for Intellectual Property Department Patentee after: Tasly Pharmaceutical Group Co., Ltd. Address before: 300402 Tianjin Beichen Xinyi white road Liaohe Road No. 1 Patentee before: Tasly Pharmaceutical Group Co., Ltd. |
|
CP01 | Change in the name or title of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: 300410 Tianjin city Beichen District Huaihe road and road intersection Dingjiang tianzhijiao Park forensic Center for Intellectual Property Department Patentee after: Tasly Pharmaceutical Group Limited by Share Ltd Address before: 300410 Tianjin city Beichen District Huaihe road and road intersection Dingjiang tianzhijiao Park forensic Center for Intellectual Property Department Patentee before: Tasly Pharmaceutical Group Co., Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120215 Termination date: 20210720 |